Author

Yoshimi Endo Greer

National Cancer InstituteORCID 0000-0002-9822-7240Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Stanley LipkowitziD· 3 shared Donna M. Voeller· 2 shared Alexei V. LobanoviD· 1 shared Anjali DhalliD· 1 shared Chuong D. HoangiD· 1 shared Danny Wangsa· 1 shared Daoud M. MeerzamaniD· 1 shared Darawalee WangsaiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Stanley LipkowitzORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma

George I Karadimov, Yoo Sun Kim, Haiqing Fu, Sidhant Narula, Fathi Elloumi, Anjali Dhall, Frank Echtenkamp, Luowei Li, Edwin J. Iwanowicz, Lee M. Graves, King Chan, Þorkell Andrésson, Robert W. Robey, Yoshimi Endo Greer, Stanley Lipkowitz, , Jaydira Del Rivero

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

bioRxiv · Aug 11, 2026 · PreprintCancer Biology

EGFR amplification and PI3K pathway mutations identify a subset of breast cancers that synergistically respond to EGFR and PI3K inhibition

David John Wisniewski, Donna M. Voeller, Yonit A. Addissie, Sachin Kumar Deshmukh, Sharon Wu, Maryam B. Lustberg, Darawalee Wangsa, Danny Wangsa, Kerstin Heselmeyer‐Haddad, Yoshimi Endo Greer, George W. Sledge, Stanley Lipkowitz

Oncogene · Nov 25, 2025Peer-reviewedCancer Biology

TRAIL-induced cytokine production via NFKB2 pathway promotes neutrophil chemotaxis and immune suppression in triple negative breast cancers

Manjari Kundu, Yoshimi Endo Greer, Alexei V. Lobanov, Lisa A. Ridnour, Renee Nicole Donahue, Yeap Ng, Shashi Ratnayake, Karley White, Donna M. Voeller, Sarah Weltz, Qingrong Chen, Stephen Lockett, Maggie Cam, Daoud M. Meerzaman, David A. Wink, , Stanley Lipkowitz

This study shows TRAIL treatment of TNBC cells activates the NFKB2 pathway, leading to cytokine production that enhances neutrophil chemotaxis and immune suppression.

Cancer Letters · Apr 6, 2025Peer-reviewedCancer Biology